Taken together, the present study indicates for the first time that aminoquinol is a new CDK4/6 and PI3K/AKT multi-kinase inhibitor and a potential candidate drug for the treatment of human HCC. The gene discussed is AKT1; the disease is hepatocellular carcinoma.